Neutralizing antibodies to Ebola virus glycoprotein and their use

US10273288B2 · kind B2 · utility

Assignees

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US
• Institute for Research in Biomedicine · CH
• The United States of America as represented by the Secretary of the Army · US
• Humabs BioMed SA · CH

Inventors

• Nancy Sullivan · Kensington, US
• Sabue Mulangu · Bethesda, US
• Davide Corti · Bellinzona, CH
• Antonio Lanzavecchia · Bellinzona, CH
• Barney Graham · Rockville, US
• Jean-Jacques Muyembe-Tamfun · Kinshasa, CD
• John Trefry · Frederick, US
• Julie Ledgerwood · Bethesda, US
• Daphne Stanley · Bethesda, US

Key dates

• Filing date: Nov 14, 2018
• Grant date: Apr 30, 2019
• Expiry date: Nov 14, 2038

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/26
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Neutralizing antibodies and antigen binding fragments that specifically bind to Ebola virus glycoprotein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting Ebola virus using the antibodies and antigen binding fragments are disclosed. The antibodies, antigen binding fragments, nucleic acids, and vectors, can be used, for example, to prevent and/or treat Ebola virus infection in a subject.